SPARC ameliorates ovarian cancer-associated inflammation

Neoplasia

Volumn 10, Issue 10, 2008, Pages 1092-1104

  Said, Neveen A ^a   Elmarakby, Ahmed A ^a   Imig, John D ^a   Fulton, David J ^a   Motamed, Kouros ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b Abraxis BioScience   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTANE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEONECTIN; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; UROKINASE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER CELL; CELL INTERACTION; CELL INVASION; COCULTURE; CONTROLLED STUDY; FEMALE; GENE ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MACROPHAGE; MACROPHAGE MIGRATION INHIBITION; MESOTHELIUM CELL; OVARY CARCINOMA; OVARY INFLAMMATION; PRIORITY JOURNAL; PROMOTER REGION; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN DEGRADATION; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION;

EID: 54249127338     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08672     Document Type: Article

References (61)

1. Paget S (1889). The distribution of secondary growths in cancers of the breast. Lancet 133, 571-573.
2. Kassis J, Klominek J, and Kohn EC (2005). Tumor microenvironment: what can effusions teach us? Diagn Cytopathol 33, 316-319.
3. Mantovani A, Bottazzi B, Sozzani S, Peri G, Allavena P, Dong QG, Vecchi A, and Colotta F (1995). Cytokine regulation of monocyte recruitment. Arch Immunol Ther Exp (Warsz) 43, 149-152.
4. Freedman RS, Deavers M, Liu J, and Wang E (2004). Peritoneal inflammation - a microenvironment for epithelial ovarian cancer (EOC). J Transl Med 2, 23.
5. Mantovani A, Bottazzi B, Colotta F, Sozzani S, and Ruco L (1992). The origin and function of tumor-associated macrophages. Immunol Today 13, 265-270.
6. Balkwill F (2003). Chemokine biology in cancer. Semin Immunol 15, 49-55.
7. Mantovani A, Schioppa T, Biswas SK, Marchesi F, Allavena P, and Sica A (2003). Tumor-associated macrophages and dendritic cells as prototypic type II polarized myeloid populations. Tumori 89, 459-468.
8. Fang XJ, Schummer M, Mao ML, Yu SX, Tabassam FH, Swaby R, Hasegawa Y, Tanyi JL, LaPushin R, Eder A, et al. (2002). Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta 1582, 257-264.
9. Lewis CE and Pollard JW (2006). Distinct role of macrophages in different tumor microenvironments. Cancer Res 66, 605-612.
10. Said N, Najwer I, and Motamed K (2007). Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer. Am J Pathol 170, 1054-1063.
11. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, and Patierno SR (2000). Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 60, 4629-4637.
12. Symowicz J, Adley BP, Woo MMM, Auersperg N, Hudson LG, and Stack MS (2005). Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells. Cancer Res 65, 2234-2242.
13. Yang L, Yamagata N, Yadav R, Brandon S, Courtney RL, Morrow JD, Shyr Y, Boothby M, Joyce S, Carbone DP, et al. (2003). Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest 111, 727-735.
14. Graves LE, Ariztia EV, Navari JR, Matzel HJ, Stack MS, and Fishman DA (2004). Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer Res 64, 7045-7049.
15. Chlenski A, Liu S, Guerrero LJ, Yang Q, Tian Y, Salwen HR, Zage P, and Cohn SL (2006). SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix. Int J Cancer 118, 310-316.
16. Chlenski A, Guerrero LJ, Yang Q, Tian Y, Peddinti R, Salwen HR, and Cohn SL (2007). SPARC enhances tumor stroma formation and prevents fibroblast activation. Oncogene 26, 4513-4522.
17. Haber CL, Gottifredi V, Llera AS, Salvatierra E, Prada F, Alonso L, Sage EH, and Podhajcer OL (2007). SPARC modulates the proliferation of stromal but not melanoma cells unless endogenous SPARC expression is downregulated. Int J Cancer 122, 1465-1475.
18. Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, and Podhajcer OL (1997). The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol 108, 210-214.
19. Dalla-Torre CA, Yoshimoto M, Lee CH, Joshua AM, de Toledo SR, Petrilli AS, Andrade JA, Chilton-MacNeill S, Zielenska M, and Squire JA (2006). Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma. BMC Cancer 6, 237.
20. Schultz C, Lemke N, Ge S, Golembieski WA, and Rempel SA (2002). Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. Cancer Res 62, 6270-6277.
21. Chen JJ, Lin YC, Yao PL, Yuan A, Chen HY, Shun CT, Tsai MF, Chen CH, and Yang PC (2005). Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol 23, 953-964.
22. Kato Y, Nagashima Y, Baba Y, Kawano T, Furukawa M, Kubota A, Yanoma S, Imagawa-Ishiguro Y, Satake K, Taguchi T, et al. (2005). Expression of SPARC in tongue carcinoma of stage II is associated with poor prognosis: an immunohistochemical study of 86 cases. Int J Mol Med 16, 263-268.
23. Brekken RA, Puolakkainen P, Graves DC, Workman G, Lubkin SR, and Sage EH (2003). Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J Clin Invest 111, 487-495.
24. Yang Q, Zage P, Kagan D, Tian Y, Seshadri R, Salwen HR, Liu S, Chlenski A, and Cohn SL (2004). Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma. Clin Cancer Res 10, 8493-8500.
25. Sato N, Fukushima N, Maehara N, Matsubayashi H, Koopmann J, Su GH, Hruban RH, and Goggins M(2003). SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 22, 5021-5030.
26. Suzuki M, Hao C, Takahashi T, Shigematsu H, Shivapurkar N, Sathyanarayana UG, Iizasa T, Fujisawa T, Hiroshima K, and Gazdar AF (2005). Aberrant methylation of SPARC in human lung cancers. Br J Cancer 92, 942-948.
27. Sova P, Feng Q, Geiss G, Wood T, Strauss R, Rudolf V, Lieber A, and Kiviat N (2006). Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev 15, 114-123.
28. Rodriguez-Jimenez FJ, Caldes T, Iniesta P, Vidart JA, Garcia-Asenjo JL, and Benito M (2007). Overexpression of SPARC protein contrasts with its transcriptional silencing by aberrant hypermethylation of SPARC CpG-rich region in endometrial carcinoma. Oncol Rep 17, 1301-1307.
29. Sangaletti S, Stoppacciaro A, Guiducci C, Torrisi MR, and Colombo MP (2003). Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma. J Exp Med 198, 1475-1485.
30. Said N and Motamed K (2005). Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am J Pathol 167, 1739-1752.
31. Yiu GK, Chan WY, Ng SW, Chan PS, Cheung KK, Berkowitz RS, and Mok SC (2001). SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 159, 609-622.
32. Mok SC, Chan WY, Wong KK, Muto MG, and Berkowitz RS (1996). SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene 12, 1895-1901.
33. Kato Y, Lewalle JM, Baba Y, Tsukuda M, Sakai N, Baba M, Kobayashi K, Koshika S, Nagashima Y, Frankenne F, et al. (2001). Induction of SPARC by VEGF in human vascular endothelial cells. Biochem Biophys Res Commun 287, 422-426.
34. Said N, Socha MJ, Olearczyk JJ, Elmarakby AA, Imig JD, and Motamed K (2007). Normalization of the ovarian cancer microenvironment by SPARC. Mol Cancer Res 5, 1015-1030.
35. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, and Balkwill FR (2005). Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 175, 1197-1205.
36. Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Pluddemann A, Charles K, Gordon S, and Balkwill FR (2006). Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol 176, 5023-5032.
37. Mestdagt M, Polette M, Buttice G, Noel A, Ueda A, Foidart JM, and Gilles C (2006). Transactivation of MCP-1/CCL2 by beta-catenin/TCF-4 in human breast cancer cells. Int J Cancer 118, 35-42.
38. Ghilardi G, Biondi ML, La Torre A, Battaglioli L, and Scorza R (2005). Breast cancer progression and host polymorphisms in the chemokine system: role of the macrophage chemoattractant protein-1 (MCP-1) 2518 G allele. Clin Chem 51, 452-455.
39. Monti P, Leone BE, Marchesi F, Balzano G, Zerbi A, Scaltrini F, Pasquali C, Calori G, Pessi F, Sperti C, et al. (2003). The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res 63, 7451-7461.
40. Kuroda T, Kitadai Y, Tanaka S, Yang X, Mukaida N, Yoshihara M, and Chayama K (2005). Monocyte chemoattractant protein-1 transfection induces angiogenesis and tumorigenesis of gastric carcinoma in nude mice via macrophage recruitment. Clin Cancer Res 11, 7629-7636.
41. Wang E, Ngalame Y, Panelli MC, Nguyen-Jackson H, Deavers M, Mueller P, Hu W, Savary CA, Kobayashi R, Freedman RS, et al. (2005). Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin Cancer Res 11, 113-122.
42. Robinson-Smith TM, Isaacsohn I, Mercer CA, Zhou M, Van Rooijen N, Husseinzadeh N, McFarland-Mancini MM, and Drew AF (2007). Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res 67, 5708-5716.
43. Hagemann T, Robinson SC, Schulz M, Trumper L, Balkwill FR, and Binder C (2004). Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis 25, 1543-1549.
44. Ahmed N, Pansino F, Clyde R, Murthi P, Quinn MA, Rice GE, Agrez MV, Mok S, and Baker MS (2002). Overexpression of alpha(v)beta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade. Carcinogenesis 23, 237-244.
45. Belli R, Amerio P, Brunetti L, Orlando G, Toto P, Proietto G, Vacca M, and Tulli A (2005). Elevated 8-isoprostane levels in basal cell carcinoma and in UVA irradiated skin. Int J Immunopathol Pharmacol 18, 497-502.
46. Rask K, Zhu Y, Wang W, Hedin L, and Sundfeldt K (2006). Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer 5, 62.
47. Spinella F, Rosano L, Di Castro V, Natali PG, and Bagnato A (2004). Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. J Biol Chem 279, 46700-46705.
48. Munkarah AR, Morris R, Baumann P, Deppe G, Malone J, Diamond MP, and Saed GM (2002). Effects of prostaglandin E(2) on proliferation and apoptosis of epithelial ovarian cancer cells. J Soc Gynecol Investig 9, 168-173.
49. Fukuda R, Kelly B, and Semenza GL (2003). Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res 63, 2330-2334.
50. Kiessling R, Kono K, Petersson M, and Wasserman K (1996). Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules. Springer Semin Immunopathol 18, 227-242.
51. Lin MT, Juan CY, Chang KJ, Chen WJ, and Kuo ML (2001). IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of anti-apoptotic gene mcl-1. Carcinogenesis 22, 1947-1953.
52. Mantovani A, Schioppa T, Porta C, Allavena P, and Sica A (2006). Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 25, 315-322.
53. Blackwell TS, Christman JW, Hagan T, Price P, Edens T, Morris PE, Wolff SN, Goodman SA, and Christman BW (2000). Oxidative stress and NF-kappaB activation: correlation in patients following allogeneic bone marrow transplantation. Antioxid Redox Signal 2, 93-102.
54. Tanaka Y, Kobayashi H, Suzuki M, Kanayama N, Suzuki M, and Terao T (2004). Upregulation of bikunin in tumor-infiltrating macrophages as a factor of favorable prognosis in ovarian cancer. Gynecol Oncol 94, 725-734.
55. Huang S, Van Arsdall M, Tedjarati S, McCarty M, Wu W, Langley R, and Fidler IJ (2002). Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 94, 1134-1142.
56. Pace E, Siena L, Ferraro M, Profita M, Mondello P, Chiappara G, Montalbano AM, Giarratano A, Bonsignore G, and Gjomarkaj M (2006). Role of prostaglandin E2 in the invasiveness, growth and protection of cancer cells in malignant pleuritis. Eur J Cancer 42, 2382-2389.
57. Chlenski A, Liu S, Crawford SE, Volpert OV, DeVries GH, Evangelista A, Yang Q, Salwen HR, Farrer R, Bray J, et al. (2002). SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res 62, 7357-7363.
58. Taghizadeh F, Tang MJ, and Tai IT (2007). Synergism between vitamin D and secreted protein acidic and rich in cysteine-induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy. Mol Cancer Ther 6, 309-317.
59. Hess LM and Alberts DS (2007). The role of intraperitoneal therapy in advanced ovarian cancer. Oncology (Williston Park) 21, 227-232 [discussion 232, 235, 239-242].
60. Munoz-Casares FC, Rufian S, Rubio MJ, Lizarraga E, Diaz-Iglesias C, Aranda E, Ciria R, Muntane J, Barrios P, Torres-Melero J, et al. (2007). Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals. Clin Transl Oncol 9, 652-662.
61. Kavanagh JJ (2007). Intraperitoneal chemotherapy in the treatment of ovarian cancer. J Surg Oncol 96, 541-542.